Biocardia Inc (NASDAQ:BCDA) — Market Cap & Net Worth
Market Cap & Net Worth: Biocardia Inc (BCDA)
Biocardia Inc (NASDAQ:BCDA) has a market capitalization of $11.78 Million ($11.78 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26465 globally and #5283 in its home market, demonstrating a -5.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biocardia Inc's stock price $1.11 by its total outstanding shares 10612734 (10.61 Million). Analyse Biocardia Inc (BCDA) cash flow conversion to see how efficiently the company converts income to cash.
Biocardia Inc Market Cap History: 2015 to 2026
Biocardia Inc's market capitalization history from 2015 to 2026. Data shows change from $1.38 Billion to $11.78 Million (-36.50% CAGR).
Index Memberships
Biocardia Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #760 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2500 of 3165 |
Weight: Biocardia Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biocardia Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biocardia Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
398.89x
Biocardia Inc's market cap is 398.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.38 Billion | $517.00K | $322.00K | 2660.36x | 4271.45x |
| 2016 | $18.57 Billion | $576.00K | -$10.31 Million | 32236.15x | N/A |
| 2017 | $3.37 Billion | $479.00K | -$12.31 Million | 7028.99x | N/A |
| 2018 | $1.72 Billion | $625.00K | -$13.99 Million | 2750.82x | N/A |
| 2019 | $585.82 Million | $710.00K | -$14.71 Million | 825.10x | N/A |
| 2020 | $550.80 Million | $145.00K | -$15.00 Million | 3798.63x | N/A |
| 2021 | $308.83 Million | $1.01 Million | -$12.62 Million | 304.27x | N/A |
| 2022 | $332.71 Million | $1.35 Million | -$11.91 Million | 246.09x | N/A |
| 2023 | $105.73 Million | $477.00K | -$11.57 Million | 221.67x | N/A |
| 2024 | $23.14 Million | $58.00K | -$7.95 Million | 398.89x | N/A |
Competitor Companies of BCDA by Market Capitalization
Companies near Biocardia Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Biocardia Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Biocardia Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Biocardia Inc's market cap moved from $1.38 Billion to $ 11.78 Million, with a yearly change of -36.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.78 Million | -11.20% |
| 2025 | $13.27 Million | -42.66% |
| 2024 | $23.14 Million | -78.12% |
| 2023 | $105.73 Million | -68.22% |
| 2022 | $332.71 Million | +7.73% |
| 2021 | $308.83 Million | -43.93% |
| 2020 | $550.80 Million | -5.98% |
| 2019 | $585.82 Million | -65.93% |
| 2018 | $1.72 Billion | -48.94% |
| 2017 | $3.37 Billion | -81.87% |
| 2016 | $18.57 Billion | +1250.00% |
| 2015 | $1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Biocardia Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.78 Million USD |
| MoneyControl | $11.78 Million USD |
| MarketWatch | $11.78 Million USD |
| marketcap.company | $11.78 Million USD |
| Reuters | $11.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more